When the companies and organisations mentioned in article R. 5124-2 become aware of the falsification or suspected falsification of medicinal products which they manufacture, operate or distribute, whether these products are distributed via the legal supply chain or by illegal means, including illegal sales via information society services, they shall inform the Agence nationale de sécurité du médicament et des produits de santé and the marketing authorisation holder without delay.